On November 12, Veradermics, Inc. fell 4.2% in Pre-Market Trading to $148.0 per share, with turnover of $129,500.
The latest identified catalyst is the market’s reassessment of the company’s recently released third-quarter results and follow-up clinical updates, even though the reported loss came in narrower than consensus expectations.
Veradermics, Inc. reported a third-quarter net loss of $21.0 million, wider than the $20.1 million loss a year earlier but better than the expected $26.5 million loss, with no revenue reported. Cash, cash equivalents and marketable securities stood at $798.4 million at September 30, which management said should fund operations into 2030. The company also highlighted positive male pattern hair loss data for VDPHL01 and said topline results from the female registration-directed Study 306 remain on track for the first half of 2027. Separately, analysts recently raised price targets, including moves to $175 and $185, but the stock showed near-term pullback despite those supportive revisions.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments